RSS-Feed abonnieren
DOI: 10.1160/TH07-09-0546
Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS)
A randomized controlled trial Financial support: This Project was funded by an unrestricted grant from the Innovations Foundation, McMaster University (representing NSERC Intellectual Property Mobilization Group), Hamilton, ON, Canada. Dr. Kearon and Dr O’Donnell are supported by the Canadian Institutes of Health Research. Dr. Kahn is a recipient of a Clinical Investigator Award from the Fonds de la Recherche en Santé du Québec.Publikationsverlauf
Received: 06. September 2007
Accepted after major revision: 05. Februar 2007
Publikationsdatum:
07. Dezember 2017 (online)
Summary
Severe post-thrombotic syndrome (PTS) is responsible for considerable disability, reduced quality of life and increased health care costs. Current therapies are limited and often ineffective. We performed a two-centre,randomized,cross-over controlled trial to evaluate Venowave TM, a novel lower-limb venous-return assist device, for the treatment of severe PTS. Eligible subjects were allocated to receive, in randomized order, Venowave for eight weeks and a control device for eight weeks. The eightweek treatment periods were separated by a four-week period when no device was used (i.e. wash-out period). The primary outcome measure was a ‘clinical success’ defined as: i) reported benefit from the device; and ii) moderate or greater improvement in symptoms of PTS; and iii) willingness to continue using the device. Secondary outcome measures included quality of life (QOL) as measured by VEINES-QOL questionnaire (higher scores indicate better QOL), and PTS severity as measured by the Villalta PTS scale (higher scores indicate more severe PTS). The study was registered with ClinicalTrials.gov (NCT00182208). Thirty-two patients were enrolled. Of these, 26 (80%) were also using graduated compression stockings. Twenty-six participants completed both trial periods. Clinical success occurred in 10 (31%) participants receiving Venowave and four (13%) participants receiving the control device, with two (6%) participants reporting a clinical success with both devices (P=0.11). Mean VEINES-QOL score at the end of study period was significantly greater (P=0.004) forVenowave (52.5; SD 5.8) compared to control (50.2;SD 6.2).MeanVillalta scale score at the end of study period was significantly decreased (P=0.004) for Venowave (12.2; SD 6.3) compared to control (15.0; SD 6.1). In conclusion,Venowave appears to be a very promising new therapy for patients with severe PTS, which may be used alone or in combination with graduated compression stockings.
-
References
- 1 Prandoni P, Lensing AW, Cogo A. et al. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
- 2 Roumen-Klapper EM, De Heijer M, Janssen MC. et al. The post-thrombotic syndrome: incidence and prognostic value of non-invasive venous examinations in a six-year follow-up study. Thromb Haemost 2005; 94: 825-830.
- 3 Leizorovicz A. Long-term consequences of deep vein thrombosis. Haemostasis 1998; 28 (Suppl. 03) 1-7.
- 4 Olin JW, Beusterien KM, Childs MB. et al. Medical costs of treating venous stasis ulcers: evidence from a retrospective cohort study. Vasc Med 1999; 4: 1-7.
- 5 Kahn SR, Ginsberg JS. The Post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev 2002; 16: 155-165.
- 6 Kahn SR. The post-thrombotic syndrome: the forgotten morbidity of deep vein thrombosis. J Thromb Thrombolysis 2006; 21: 41-48.
- 7 Kahn SR, Hirsch A, Shrier I. Effect of post-thrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med 2002; 162: 1144-1148.
- 8 Kahn SR, Ducruet T, Lamping DL. et al. Prospective evaluation of health-related quality of life in patients with deep venous thrombosis. Arch Intern Med 2005; 165: 1173-1178.
- 9 Brandjes DPM, Büller HR, Heijboer H. et al. Randomised trial of effect of compression stockings in subjects with symptomatic proximal-vein thrombosis. Lancet 1997; 349: 759-762.
- 10 Prandoni P, Lensing AW, Prins MH. et al. Belowknee elastic compression stockings to prevent the postthrombotic syndrome: a randomized, controlled trial. Ann Intern Med 2004; 141: 249-256.
- 11 Ginsberg JS, Hirsh J, Julian J. et al Prevention and treatment of Postphlebitic Syndrome. Results of a 3-Part Study. Arch Intern Med 2001; 161: 2105-2109.
- 12 Ginsberg JS, Magier D, McKinnon B. et al. Intermittent compression units for severe post-thrombotic syndrome: a randomized crossover study. CMAJ 1999; 160: 1303-1306.
- 13 O’Donnell M, Ginsberg JS, Saringer J. et al Effects of a novel Venous-return assist device (‘Venowave’) on lower limb venous flow in Subjects with post-thrombotic syndrome. Blood 2002; 100 (Suppl. 11) 3950.
- 14 O’Donnell M, Ginsberg JS, Saringer J. et al. Evaluation of a venous-return assist device (Venowave) to treat post-thrombotic syndrome: A phase II study. Poster presentation at the International Society of Thrombosis and Haemostasis. July 2003
- 15 Villalta S, Bagatella P, Piccioli A. et al. Assessment and validity and reproducibility of a clinical scale for the post-thrombotic syndrome. Hemostasis 1994; 24 (Suppl. 01) 158a Abstract.
- 16 Lamping DL, Schroter S, Kurz X. et al. Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. J Vasc Surg 2003; 37: 410-419.
- 17 Kahn SR, Lamping DL, Ducruet T. et al. VEINESQOL/ Sym questionnaire was a reliable and valid disease- specific quality of life measure for deep venous thrombosis. J Clin Epidemiol 2006; 59: 1049-1056.